MIRA INFORM REPORT

 

 

Report Date :

03.11.2014

 

IDENTIFICATION DETAILS

 

Name :

BAYER PHARMACEUTICALS PRIVATE LIMITED

 

 

Formerly Known As :

BAYER ZYDUS HEALTHCARE PRIVATE LIMITED

 

 

Registered Office :

Olympia, First Floor, Central Avenue, Hiranandani Gardens, Powai, Mumbai – 400076, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2014

 

 

Date of Incorporation :

29.07.1998

 

 

Com. Reg. No.:

11-116021

 

 

Capital Investment / Paid-up Capital :

Rs. 263.200 Millions

 

 

CIN No.:

[Company Identification No.]

U05195MH1998PTC116021

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

MUMB08712E

 

 

PAN No.:

[Permanent Account No.]

AABCB3852F

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Manufacturer, Seller and Distribution of Pharma and Animal Health Products and also Seller and Distribution of Diabetes Care Products.

 

 

No. of Employees :

Information declined by the management

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba (54)

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 1200000

 

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Exist

 

 

Comments :

Subject is a subsidiary of “BAYER (SOUTH EAST ASIA) PTE LIMITED”. It is a well-established company having fine track record.

 

A reserve of the company is low.

 

However, the rating takes into consideration company’s improved operational performance supported by profit achieved from operations during 2014 and strong operational as well as financial support that the company receives from its parent company.

 

Trade relations are reported as fair. Business is active. Payments are reported to be regular and as per commitment.

 

The company can be considered good for normal business dealings at usual trade terms and conditions. 

 

NOTES:

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 1, 2014

 

Country Name

Previous Rating

(31.03.2014)

Current Rating

(01.06.2014)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INDIAN ECONOMIC OVERVIEW

 

N E W S

 

Verdict Implications : Apex court order may alter coal import dynamics. Traders go slow on talks over coal supply contracts, uncertainty over cancellation of blocks weigh on stocks.

 

Recent arrest of the Chennai head of the Registrar of Companies, the ministry of corporate affairs arm that ensures that companies file all the information required by the Companies Act is the latest manifestation of a messy fight between a father and his adopted son for the control of Rs 40000 mn business empire. The Central Bureau of Investigation arrested Manumeethi Cholan after he accepted Rs 10 lakhs as bribe from M A M Ramaswamy, a CBI official said.

 

Central Bureau of Investigation books Electrotherm for cheating Central Bank of Rs 4360 mn.

 

Infosys maintains revenue guidance. COO Rao says attrition still an area of concern and it would take a few more quarters to bring down levels to 13-15 %.

 

DHL  to invest Euro 100 mn in India over next 2 years. The firm has chosen India to pilot its e-commerce business model for the Asia-Pacific region.

 

Blackstone may buy stake in BlueRidge SEZ in line with the fund’s real estate strategy in India.

 

Kingfisher Airlines Ltd grounded in October 2012 under the weight of heavy debt and accumulated losses, recently approached the Delhi high court for relief in two separate cases. The airline challenged a notice by Punjab & National Bank alleging that It had wilfully defaulted on Rs 7700 mn of loans and sought more time to comply with the requirements under the listing agreements with the Stock Exchanges.

 

OnMobile likely to sack another 300 employees. The lay-offs follow a spate of senior-level exits over the past two years, starting with of its founder. The overall lay-offs could number around 600 and are driven by the need to cut costs, says a former employee.

 

 

 

EXTERNAL AGENCY RATING

 

Rating Agency Name

CRISIL

Rating

Long term rating=A

Rating Explanation

Adequate degree of safety and low credit risk.

Date

08.04.2014

 

 

Rating Agency Name

CRISIL

Rating

Short term rating=A1

Rating Explanation

Very strong degree of safety and lowest credit risk.

Date

08.04.2014

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2014.

 

 

INFORMATION DENIED

 

Management Non Co-operative (91-22-25311234)

 

 

LOCATIONS

 

Registered Office :

Olympia, First Floor, Central Avenue, Hiranandani Gardens, Powai, Mumbai – 400076, Maharashtra, India

Tel. No.:

91-22-25711234

Fax No.:

91-22-25700147/ 25455080/ 25705940

E-Mail :

dhananjay.bhagwat@bayercropscience.com

dhananjay.bhagwat@bayer.com

vikas.soni@bayer.com

padmashri.joshi@bayer.com

Website :

http://www.bayergroupindia.com

 

 

Head Office:

Kolshet Road, Thane – 400607, Maharashtra, India

Tel. No.:

91-22-5311234

 

 

Branch Office 1 :

1st Floor, 9 Harleys Road, Kilpauk, Chennai – 600010, Tamilnadu, India

Tel. No.:

91-44-26453730

Fax No.:

91-44-26453740

 

 

Branch Office 2 :

ECOSPACE, Building No.3A, Unit No. 502, 5th Floor, 59 M Wide (R.O.W) Road, New Town, Rajarhat, Kolkata – 700156, West Bengal, India

Tel. No.:

91-33-66227123

Fax No.:

91-33-66227198/ 99

 

 

DIRECTORS

 

AS ON 27.09.2013

 

Name :

Angel Michaelo Luna Evangelista

Designation :

Managing director

Address :

Flat No. 502, 5th Floor, Evita Building, Hiranandani Gardens, Powai, Mumbai - 400076, Maharashtra, India

Date of Birth/Age :

06.10.1965

Qualification :

B.Sc., Dipl in Industrial Engineering, MBM, MBA

Experience :

16 Years

Date of Appointment :

01.07.2011

PAN No.:

AAVPE4411C

DIN No.:

03030559

 

 

Name :

Fidahusein Yacub Merchant

Designation :

Director

Address :

201, Louella, Plot No. 443, TPS 3, 14th Road, Bandra, Mumbai – 400050, Maharashtra, India

Date of Birth/Age :

03.04.1958

Date of Appointment :

30.05.2007

DIN No.:

01239956

 

 

Name :

Mr. Biren Pravinchandra Dave

Designation :

Director

Address :

Flat No. 401, 4th Floor, Resort View Cooperative Housing Society Limited, Thakur Complex, Kandivali (East), Mumbai - 400101, Maharashtra, India

Date of Birth/Age :

01.07.1970

Date of Appointment :

30.05.2007

DIN No.:

01236596

 

 

KEY EXECUTIVES

 

Name :

Mr. Dhananjay Manohar Bhagwat

Designation :

Secretary

Address :

B-12, Ghanashyam Society, Dr. Rajendra Prasad Road, Opposite Ram Nagar, Post Office, Dombivali, Thane - 421201, Maharashtra, India

Date of Birth/Age :

20.04.1976

Date of Appointment :

30.04.2007

PAN No.:

AIYPB4398Q

 

 

Name :

Mr. Rajesh Aggarwal

Designation :

Country Group Head – Southern Asia

 

 

Name :

Mr. Vishwanath Nilakantan

Designation :

Manager - National Key Accounts

 

 

Name :

Mr. Mayank Tripathi

Designation :

Leadership Associate

 

 

Name :

Mr. Santanu Rudra

Designation :

Head - Marketing

 

 

Name :

Mr. Nilesh Nayak

Designation :

Head - Training

 

 

Name :

Mr. Manoj Saxena

Designation :

Business Unit Head – General Medicine

 

 

Name :

Mr. Rakesh Julka

Designation :

Country Division Head - Diabetes Care

 

 

Name :

Mr. Pradeep Sharma

Designation :

Businees Unit Head – Speciality Products

 

 

Name :

N.V. Chalapathi Rao

Designation :

Chief Administrative Officer

 

 

MAJOR SHAREHOLDERS

 

AS ON 27.09.2013

 

Names of Equity Shareholders

 

No. of Shares

Bayer (South East Asia) Pte. Limited, Singapore

21316699

Bayer South East Asia Pte. Limited, Singapore Jointly with Shirin V. Balsara

1

Bayer South East Asia Pte. Limited, Singapore Jointly with Pradnesh Kamat

1

 

 

Total

21316701

 

 

Names of Preference Shareholders

 

No. of Shares

Bayer Material Science Private Limited, India

5000000

 

 

Total

5000000

 

 

 

Equity Share Break up (Percentage of Total Equity)

 

AS ON 27.09.2013

 

Category

Percentage

Foreign holdings( Foreign institutional investor(s), Foreign companie(s) Foreign financial institution(s), Non-resident Indian(s) or Overseas Corporate bodies or Others

100.00

 

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer, Seller and Distribution of Pharma and Animal Health Products and also Seller and Distribution of Diabetes Care Products.

 

 

GENERAL INFORMATION

 

No. of Employees :

Information declined by the management

 

 

Bankers :

·         HDFC Bank Limited

·         Union Bank of India

 

 

 

Banking Relations :

--

 

 

Auditors :

 

Name :

Price Waterhouse

Chartered Accountants

Address :

Plot YOY 14, Block EP, Sector V, Salt Lake Electronic Complex, Bidhan Nagar, Kolkata – 700091, West Bengal, India

PAN No.:

AAEFP3641G

 

 

Ultimate Holding company :

Bayer AG, Germany

 

 

Holding company :

Bayer (South East Asia) Pte Limited, Singapore

 

 

Parties under Common Control * :

·         AgraQuest Inc., U.S.A.

·         Bayer (Malaysia) Sdn. Bhd., Malaysia

·         Bayer Animal Health GmbH, Germany

·         Bayer Australia Limited, Australia

·         Bayer BioScience Private Limited, India

·         Bayer Business Services GmbH, Germany

·         Bayer Business Services Private Limited, India (merged with Bayer MaterialScience Private Limited, India effective from April 1, 2013)

·         Bayer Consumer Care AG, Switzerland

·         Bayer CropScience Limited, India

·         Bayer Direct Services GmbH, Germany

·         Bayer El Salvador, El Salvador

·         Bayer HealthCare AG, Germany

·         Bayer Healthcare Limited, Hong Kong

·         Bayer HealthCare LLC, U.S.A.

·         Bayer Korea Limited, Korea

·         Bayer MaterialScience Private Limited, India

·         Bayer New Zealand Limited, New Zealand

·         Bayer Pharma AG, Germany

·         Bayer Thai Company Limited, Thailand

·         Bayer Vapi Private Limited, India (formerly Bilag Industries Private Limited)

·         Bayer Vietnam Limited, Vietnam

·         KVP Pharma+Veterinar Produkte GmbH, Germany

·         Medrad Asia Pte Limited, Singapore

·         Nunhems India Private Limited, India

 

* The list of parties above have been limited to those with whom transactions have taken place during the year or balances are outstanding as at the year-end.

 

 

Enterprise where Key Managerial Personnel has significant influence :

Bayer Zydus Pharma Private Limited, India

 


 

CAPITAL STRUCTURE

 

AS ON 27.09.2013

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

22240000

Equity Shares

Rs.10/- each

Rs.222.400 Millions

12000000

Preference Shares

Rs.10/- each

Rs.120.000 Millions

 

 

 

 

 

Total

 

Rs.342.400 Millions

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

21316701

Equity Shares

Rs.10/- each

Rs.213.167 Millions

5000000

Preference Shares

Rs.10/- each

Rs.50.000 Millions

 

 

 

 

 

Total

 

Rs.263.167 Millions

 


FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2014

31.03.2013

31.03.2012

I.              EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

263.200

263.200

263.200

(b) Reserves & Surplus

152.200

91.000

123.800

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

415.400

354.200

387.000

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

0.000

0.000

0.000

(b) Deferred tax liabilities (Net)

0.000

0.000

0.000

(c) Other long term liabilities

6.600

4.800

3.300

(d) long-term provisions

23.400

18.800

16.900

Total Non-current Liabilities (3)

30.000

23.600

20.200

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

173.300

50.000

187.400

(b) Trade payables

170.800

217.900

194.600

(c) Other current liabilities

69.500

43.300

60.400

(d) Short-term provisions

10.500

11.900

11.500

Total Current Liabilities (4)

424.100

323.100

453.900

 

 

 

 

TOTAL

869.500

700.900

861.100

 

 

 

 

II.            ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

5.300

9.400

10.900

(ii) Intangible Assets

3.400

15.700

19.000

(iii) Capital work-in-progress

0.000

0.000

4.900

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

200.000

200.000

0.000

(c) Deferred tax assets (net)

24.100

0.000

25.700

(d)  Long-term Loan and Advances

69.300

51.700

25.100

(e) Other Non-current assets

0.000

0.000

0.000

Total Non-Current Assets

302.100

276.800

85.600

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

250.300

280.100

347.700

(c) Trade receivables

228.200

108.900

376.500

(d) Cash and cash equivalents

29.900

17.900

16.900

(e) Short-term loans and advances

20.100

17.200

34.400

(f) Other current assets

38.900

0.000

0.000

Total Current Assets

567.400

424.100

775.500

 

 

 

 

TOTAL

869.500

700.900

861.100

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

 

31.03.2014

31.03.2013

31.03.2012

 

SALES

 

 

 

 

 

Income

1427.100

1498.800

1834.700

 

 

Other Operating Income & Other Income

152.300

219.700

185.100

 

 

TOTAL                                            

1579.400

1718.500

2019.800

 

 

 

 

 

Less

EXPENSES

1521.400

1711.400

1699.500

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX 

58.000

7.100

320.300

 

 

 

 

 

Less

TAX                                                                 

(3.200)

39.900

119.200

 

 

 

 

 

 

PROFIT/(LOSS) AFTER TAX

61.200

(32.800)

201.100

 

 

 

 

 

 

Earnings/(Loss) Per Share (Rs.)

2.87

(1.54)

9.43

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2014

31.03.2013

31.03.2012

Net Profit Margin

PAT / Sales

(%)

4.29

(2.19)

10.96

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

8.99

1.42

38.57

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.14

0.02

0.83

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

0.42

0.14

0.48

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.34

1.31

1.71

 

FINANCIAL ANALYSIS

[all figures are in Rupees Millions]

 

DEBT EQUITY RATIO

 

Particular

31.03.2012

31.03.2013

31.03.2014

 

Rs. In Millions

Rs. In Millions

Rs. In Millions

Share Capital

263.200

263.200

263.200

Reserves & Surplus

123.800

91.000

152.200

Net worth

387.000

354.200

415.400

 

 

 

 

long-term borrowings

0.000

0.000

0.000

Short term borrowings

187.400

50.000

173.300

Total borrowings

187.400

50.000

173.300

Debt/Equity ratio

0.484

0.141

0.417

 

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2012

31.03.2013

31.03.2014

 

Rs. In Millions

Rs. In Millions

Rs. In Millions

Sales

1834.700

1498.800

1427.100

 

 

(18.308)

(4.784)

 

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2012

31.03.2013

31.03.2014

 

Rs. In Millions

Rs. In Millions

Rs. In Millions

Sales

1834.700

1498.800

1427.100

Profit

201.100

(32.800)

61.200

 

10.96%

(2.19%)

4.29%

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

No

9]

Name of person contacted

No

10]

Designation of contact person

No

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

-----------

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

Yes

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

----------

22]

Litigations that the firm / promoter involved in

Yes

23]

Banking Details

Yes

24]

Banking facility details

No

25]

Conduct of the banking account

----------

26]

Buyer visit details

----------

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

Yes

LITIGATION DETAILS:

 

 

HIGH COURT OF BOMBAY

 

Case Details

 

Bench:-Bombay

 

Lodging No.:-

CCL/1831/2012

Filing Date:-

16/07/2012

Reg. No.:-

CC/3/2014

Reg. Date:-

05/03/2014

 

 

Petitioner:-

M.JL. CHEMPHARM PVT. LTD. AND INNOVA LIF

Respondent:-

BAYER CORPORATION AND ANR -

 

Petn.Adv.:-

M/S. KARTIKEYA & DESAI (U/OBJ) ()

 

District:-

MUMBAI

 

 

Bench:-

SINGLE

Status:-

Pre-Admission

Category:-

COUNTER CLAIM

 

Last Date:-

08/02/2014

Stage:-

FOR REJECTION [ORIGINAL SIDE MATTERS]

 

 

Last Coram:-

HON’BLE SHRI JUSTICE S.J. KATHAWALLA

 

 

 

Act :-

Code of Civil Procedure 1908

 

 

NOTE:

 

The registered office of the company has been shifted from Bayer House, Central Avenue, Hiranandani Gardens, Powai, Mumbai - 400076, Maharashtra, India to the present w.e.f.01.06.2013

 

 

OPERATIONS DURING THE YEAR:

 

During the year, subject has earned a total income of Rs.1579.400 Millions (previous year Rs.1718.500 Millions) which includes Other Operating Income and Other Income of Rs.152.300 Millions (previous financial period Rs. 219.700 Millions). After meeting the operative expenses, subject’s profit before tax is Rs.58.000 Millions (as compared to loss of Rs.7.100 Millions in the previous financial year).

 

 

UNSECURED LOANS:

 

Particulars

31.03.2014

Rs. In Millions

31.03.2013

Rs. In Millions

Short Term Borrowings

 

 

Loans repayable on demand from banks

81.300

50.000

Intercorporate deposits

92.000

0.000

 

 

 

Total

173.300

50.000

 

 

NO CHARGES EXIST FOR COMPANY.

 

FIXED ASSETS:

 

·         Plant and equipment

·         Furniture and fixtures

·         Vehicles

·         Office equipment

·         Goodwill

·         Computer software

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                                       None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.61.41

UK Pound

1

Rs.98.06

Euro

1

Rs.77.19

 

 

INFORMATION DETAILS

 

Information Gathered by :

HNA

 

 

Analysis Done by :

KRN

 

 

Report Prepared by :

NKT


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

6

PAID-UP CAPITAL

1~10

6

OPERATING SCALE

1~10

6

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

6

--PROFITABILIRY

1~10

6

--LIQUIDITY

1~10

6

--LEVERAGE

1~10

6

--RESERVES

1~10

6

--CREDIT LINES

1~10

6

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

NO

--LITIGATION

YES/NO

YES

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

 

 

 

TOTAL

 

54

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NB

NEW BUSINESS

 

 

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.